HUE065440T2 - Anti-BK-vírus antitestmolekulák - Google Patents

Anti-BK-vírus antitestmolekulák

Info

Publication number
HUE065440T2
HUE065440T2 HUE21730952A HUE21730952A HUE065440T2 HU E065440 T2 HUE065440 T2 HU E065440T2 HU E21730952 A HUE21730952 A HU E21730952A HU E21730952 A HUE21730952 A HU E21730952A HU E065440 T2 HUE065440 T2 HU E065440T2
Authority
HU
Hungary
Prior art keywords
antibody molecules
virus antibody
virus
molecules
antibody
Prior art date
Application number
HUE21730952A
Other languages
English (en)
Inventor
Marcel Weber
Simone Schmitt
Christoph Esslinger
Thomas Schachtner
Uyen Huynh-Do
Maurizio Provenzano
Original Assignee
Memo Therapeutics Ag
Univ Bern
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memo Therapeutics Ag, Univ Bern, Univ Zuerich filed Critical Memo Therapeutics Ag
Publication of HUE065440T2 publication Critical patent/HUE065440T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35Valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01DNA viruses
    • G01N2333/025Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
HUE21730952A 2020-06-09 2021-06-09 Anti-BK-vírus antitestmolekulák HUE065440T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20179044 2020-06-09
EP20179041 2020-06-09

Publications (1)

Publication Number Publication Date
HUE065440T2 true HUE065440T2 (hu) 2024-05-28

Family

ID=76325565

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE21730952A HUE065440T2 (hu) 2020-06-09 2021-06-09 Anti-BK-vírus antitestmolekulák

Country Status (25)

Country Link
US (2) US11919943B2 (hu)
EP (2) EP4327883A3 (hu)
JP (1) JP2023528828A (hu)
KR (1) KR20230035578A (hu)
CN (1) CN115776988A (hu)
AU (1) AU2021288986A1 (hu)
BR (1) BR112022024288A2 (hu)
CA (1) CA3181750A1 (hu)
CL (1) CL2022003491A1 (hu)
CO (1) CO2023000070A2 (hu)
DK (1) DK4126932T5 (hu)
ES (1) ES2971001T3 (hu)
FI (1) FI4126932T3 (hu)
HR (1) HRP20231739T1 (hu)
HU (1) HUE065440T2 (hu)
IL (1) IL298803A (hu)
LT (1) LT4126932T (hu)
MX (1) MX2022015071A (hu)
PE (1) PE20231444A1 (hu)
PL (1) PL4126932T3 (hu)
PT (1) PT4126932T (hu)
RS (1) RS65172B1 (hu)
SI (1) SI4126932T1 (hu)
WO (1) WO2021250097A1 (hu)
ZA (1) ZA202212136B (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023528828A (ja) 2020-06-09 2023-07-06 メモ テラポイティクス アクチェンゲゼルシャフト 抗bkウイルス抗体分子
WO2023175171A1 (en) * 2022-03-18 2023-09-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Bk polyomavirus antibodies and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9771413B2 (en) * 2012-12-31 2017-09-26 Neurimmune Holding Ag Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
US11433132B2 (en) * 2017-12-01 2022-09-06 Novartis Ag Polyomavirus neutralizing antibodies
JP2023528828A (ja) 2020-06-09 2023-07-06 メモ テラポイティクス アクチェンゲゼルシャフト 抗bkウイルス抗体分子

Also Published As

Publication number Publication date
EP4126932B1 (en) 2023-11-15
LT4126932T (lt) 2024-02-12
MX2022015071A (es) 2023-02-27
FI4126932T3 (fi) 2024-01-18
AU2021288986A1 (en) 2022-12-15
ES2971001T3 (es) 2024-06-03
PE20231444A1 (es) 2023-09-14
HRP20231739T1 (hr) 2024-03-15
EP4327883A2 (en) 2024-02-28
CL2022003491A1 (es) 2023-08-11
CN115776988A (zh) 2023-03-10
PT4126932T (pt) 2024-01-18
SI4126932T1 (sl) 2024-03-29
EP4327883A3 (en) 2024-05-22
CA3181750A1 (en) 2021-12-16
BR112022024288A2 (pt) 2023-01-31
US20230192816A1 (en) 2023-06-22
WO2021250097A1 (en) 2021-12-16
CO2023000070A2 (es) 2023-02-16
ZA202212136B (en) 2024-02-28
DK4126932T5 (da) 2024-07-22
PL4126932T3 (pl) 2024-04-22
IL298803A (en) 2023-02-01
US20240132575A1 (en) 2024-04-25
US20240228590A9 (en) 2024-07-11
EP4126932A1 (en) 2023-02-08
US11919943B2 (en) 2024-03-05
RS65172B1 (sr) 2024-03-29
KR20230035578A (ko) 2023-03-14
DK4126932T3 (da) 2024-01-22
JP2023528828A (ja) 2023-07-06

Similar Documents

Publication Publication Date Title
IL275510A (en) Specific antigen-binding molecules-ROR1
HK1250737A1 (zh) 結合cd79的抗體分子
DK3645571T3 (da) Her3-antigen-bindende molekyler
DK3645570T3 (da) VISTA-antigenbindende molekyler
EP3452107A4 (en) DNA MONOCLONAL ANTIBODIES AGAINST CHECKPOINT MOLECULES
IL280004A (en) Antibody molecules that bind PD-L1 and CD137
GB202020154D0 (en) ROR1-specific variant antigen binding molecules
IL280002A (en) Antibody molecules that bind CD137 and OX40
GB2595980B (en) Anti-TCR antibody molecules and uses thereof
MX2022001220A (es) Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
GB201811403D0 (en) Antibody molecules
ZA202007259B (en) Bispecific antibody against rabies virus, and application thereof
KR101882087B1 (ko) 어류 바이러스성 출혈성 패혈증 바이러스에 특이적인 단클론항체 및 이의 용도
RS65172B1 (sr) Molekuli antitela protiv bk virusa
GB2607452B (en) Anti-TCR antibody molecules and uses thereof
IL292799A (en) Antibodies against siglec-9
GB2598218B (en) Anti-TCR antibody molecules and uses thereof
EP4063383A4 (en) ANTIBODIES AGAINST VARICELLA ZOSTER VIRUS
KR20220016865A9 (ko) 항원 결합 분자, 약학 조성물, 및 방법
EP3452504A4 (en) MONOCLONAL DNA ANTIBODIES AGAINST INFLUENCE VIRUS
GB201820446D0 (en) Antigen binding molecules that bind light
TWI847989B (zh) 結合cd137及ox40的抗體分子
GB201902598D0 (en) Antibody molecules that bind cd137 and ox40
GB201818281D0 (en) Antibody molecules that bind CD137 and OX40
GB201818283D0 (en) Antibody molecules that bind PD-L1 and CD137